PT  - JOURNAL ARTICLE
AU  - Henrik Isackson
AU  - Anders Larsson
AU  - Miklos Lipcsey
AU  - Robert Frithiof
AU  - Frank A. Flachskampf
AU  - Michael Hultström
TI  - Echocardiographic characterisation in critical Covid19 - an observational study
AID  - 10.1101/2021.07.23.21261025
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.23.21261025
4099  - http://medrxiv.org/content/early/2021/09/24/2021.07.23.21261025.short
4100  - http://medrxiv.org/content/early/2021/09/24/2021.07.23.21261025.full
AB  - Objective We aimed to investigate the acute cardiac effects of severe SARS-CoV-2.Methods This is an observational study generated from the first 79 patients admitted to Uppsala intensive care due to respiratory failure with SARS-CoV-2 infection. 34 underwent echocardiography of which 25 were included in the study and compared to 44 non-echo patients. Exclusion was based on absence of normofrequent sinus rhythm and mechanical respiratory support. Biomarker analysis was carried out on all patients.Results Mortality was increased in the echo compared to non-echo group (44 % vs. 16%, p<0.05). Right sided dimensions and functional parameters were not affected. Tricuspid regurgitation velocity indicated how increased pulmonary artery pressure was associated with mortality (survivors (n=5): 2.51 ± 0.01 m/s vs. non-survivors (n=5): 3.06 ± 0.11 m/s, p<0.05). Cardiac markers and D-dimer correlated to initiation of echocardiography (hs-TnI (ng/L): echo (n=23): 133 ± 45 vs. non-echo (n=41): 81.3 ± 45, p<0.01; NTproBNP (ng/L): echo (n=25): 2959 ± 573 vs. non-echo (n=42): 1641 ± 420, p<0.001; D-dimer (mg/L): echo (n=25): 16.1 ± 3.7 vs. non-echo (n=43: 6.1 ± 1.5, p<0.01) and mortality (hs-TnI (ng/L): survivors (n=48): 59.1 ± 21 vs. non-survivors (n=17): 211 ± 105, p<0.0001; NT-proBNP (ng/L): survivors (n=47): 1310 ± 314 vs. non-survivors (n=20): 4065 ± 740, p<0.0001; D-dimer (mg/L): survivors (n=50): 7.2 ± 1.5 vs. non-survivors (n=18): 17.1 ± 4.8, p<0.01). All intervals refer to standard error of the mean. Tricuspid regurgitation velocity was correlated with troponin I (r=0.93, r2=0.74, p<0.001, n=10).Conclusions These results suggest that there is no clear negative effect on cardiac function in critical SARS-CoV-2. There are indications that pulmonary pressure elevation carries a negative predictive outcome suggesting pulmonary disease as the driver of mortality. Cardiac biomarkers as well as D-dimer carry predictive value.Trial registration number Patients were included in “Clinical trials NCT04316884”Strength and limitations of this study- The patient body is recruited from all patients admitted to ICU in need of mechanical respiratory support independent of background which makes it relevant to clinical practice.- The echocardiographic image acquisition was carried out by hospital assigned agents on clinical indication, which makes the results applicable in a clinical setting.- Since the image acquisition was carried out on a clinical indication, the results may be skewed towards the false positive if applied to all Covid19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04316884Funding StatementThe study was funded by the SciLifeLab/KAW national Covid-19 research program project grants to MH (KAW 2020.0182 and KAW 2020.0241), and the Swedish Research Council to RF (2014-02569 and 2014-07606). HI was supported by the Swedish Society of Medical Research (SSMF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Swedish National Ethical Review Authority EPM; 2020-01623All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from the author upon reasonable requestAatrial transmitral diastolic velocityACE-2angiotensin converting enzyme 2ACEiangiotensin converting enzyme inhibitorARBangiotensin receptor blockerAngangiotensinBMIbody mass indexCovid-19corona virus disease 2019Eearly transmitral diastolic velocitye’medial tissue diastolic velocityEACVIEuropean association of cardiovascular imagingESCEuropean society of cardiologyFACfractional area changeGLSglobal longitudinal strainhs-TnIhigh sensitivity troponin IICUintensive care unitIVCinferior vena cavaIVC resp. variationinferior vena cava respiratory variationIVSDinterventricular septum diameterLAleft atriumLVleft ventricleLVEDDleft ventricular end diastolic diameterLVEFleft ventricular ejection fractionLVPWDleft ventricular posterior wall end diastolic diameterMV dec. timemitral valve deceleration timensnot significantNT-proBNPN-terminal pro brain natriuretic peptidePHpulmonary hypertensionPAATpulmonary artery acceleration timeRAright atriumRVright ventricleRVD1right ventricular basal diameterSARS-CoV-2severe acute respiratory syndrome corona virus 2TAPSEtricuspid annular peak systolic excursionTR Vmaxmaximum tricuspid regurgitation velocity